Join Growin Stock Community!

Sangamo therapeutics, inc.SGMO.US Overview

US StockHealthcare
(No presentation for SGMO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SGMO AI Insights

SGMO Overall Performance

SGMO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SGMO Recent Performance

-3.31%

Sangamo therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

SGMO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SGMO Key Information

SGMO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SGMO Profile

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

Price of SGMO

SGMO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SGMO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.29
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4.89
PB Ratio
26.80
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-331.28%
Revenue Growth (YoY)
-37.13%
Profit Growth (YoY)
-37.13%
3-Year Revenue Growth
-72.00%
3-Year Profit Growth
-72.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.29
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4.89
PB Ratio
26.80
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-331.28%
Revenue Growth (YoY)
-37.13%
Profit Growth (YoY)
-37.13%
3-Year Revenue Growth
-72.00%
3-Year Profit Growth
-72.00%

  • When is SGMO's latest earnings report released?

    The most recent financial report for Sangamo therapeutics, inc. (SGMO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SGMO's short-term business performance and financial health. For the latest updates on SGMO's earnings releases, visit this page regularly.

  • What is the operating profit of SGMO?

    According to the latest financial report, Sangamo therapeutics, inc. (SGMO) reported an Operating Profit of -35.55M with an Operating Margin of -6,119.28% this period, representing a decline of 434.43% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is SGMO's revenue growth?

    In the latest financial report, Sangamo therapeutics, inc. (SGMO) announced revenue of 581K, with a Year-Over-Year growth rate of -98.82%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does SGMO have?

    At the end of the period, Sangamo therapeutics, inc. (SGMO) held Total Cash and Cash Equivalents of 30.53M, accounting for 0.34 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does SGMO go with three margins increasing?

    In the latest report, Sangamo therapeutics, inc. (SGMO) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -6,119.28%%, and net margin of -6,012%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess SGMO's profit trajectory and future growth potential.

  • Is SGMO's EPS continuing to grow?

    According to the past four quarterly reports, Sangamo therapeutics, inc. (SGMO)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.11. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SGMO?

    Sangamo therapeutics, inc. (SGMO)'s Free Cash Flow (FCF) for the period is -28.56M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 345.29% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.